Abbott in-licenses monoclonal antibody from Pierre Fabre
This article was originally published in Scrip
Executive Summary
Abbott is to pay $25 million up-front to Pierre Fabre for the development and commercialisation rights to the French firm's anticancer candidate h224G11.